Dermata Therapeutics (DRMA) Total Non-Current Liabilities (2020 - 2022)
Dermata Therapeutics (DRMA) posted quarterly Total Non-Current Liabilities of $496702.0 for Q4 2022, down 3.6% year-over-year from $515245.0 in Q4 2021, and up 2.68% quarter-over-quarter from $483741.0 in Q3 2022.
Dermata Therapeutics (DRMA) Total Non-Current Liabilities (2020 - 2022) Analysis & Trends
Dermata Therapeutics' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $496702.0 for Q4 2022.
- In Q4 2022, Total Non-Current Liabilities fell 3.6% year-over-year to $496702.0; the TTM figure through Dec 2022 stood at $496702.0 (down 3.6% YoY), while the FY2022 annual figure was $496702.0, down 3.6% from the prior year.
- Total Non-Current Liabilities for Q4 2022 stood at $496702.0, up from $483741.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $3.6 million in Q4 2020, with the low at $483741.0 in Q3 2022.
- The 3-year median for Total Non-Current Liabilities is $635520.5 (2022), against an average of $1.0 million.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities plunged 85.88% in 2021, then slipped 3.6% in 2022.
- Dermata Therapeutics' Total Non-Current Liabilities stood at $3.6 million in 2020, then slumped by 85.88% to $515245.0 in 2021, then slipped by 3.6% to $496702.0 in 2022.
- Business Quant data shows DRMA's Total Non-Current Liabilities at $496702.0 in Q4 2022, $483741.0 in Q3 2022, and $608811.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 9.32 Bn |
| 10 | Dermata Therapeutics | 5.38 Mn | 5.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 496,702.00 |
| Sep 30, 2022 | 483,741.00 |
| Jun 30, 2022 | 608,811.00 |
| Mar 31, 2022 | 662,230.00 |
| Dec 31, 2021 | 515,245.00 |
| Sep 30, 2021 | 769,863.00 |
| Jun 30, 2021 | 1.06 Mn |
| Dec 31, 2020 | 3.65 Mn |